purpose
Previously published guidelines are available that provide comprehensive recommendations for detecting and preventing healthcare-associated infections (HAIs). The intent of this document is to highlight practical recommendations in a concise format designed to assist acute care hospitals in implementing and prioritizing their Clostridium difficile infection (CDI) prevention efforts. This document updates "Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals," 1 published in 2008. This expert guidance document is sponsored by the Society for Healthcare Epidemiology of America (SHEA) and is the product of a collaborative effort led by SHEA, the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise. The list of endorsing and supporting organizations is presented in the introduction to the 2014 updates. 2 section 1: rationale and statements of concern I. Increasing rates of CDI C. difficile now rivals methicillin-resistant Staphylococcus aureus (MRSA) as the most common organism to cause HAIs in the United States. [3] [4] [5] A. In the United States, the proportion of hospital discharges in which a patient received the International Classification of Diseases, Ninth Revision, Clinical Modification discharge diagnosis code for CDI more than doubled between 2000 and 2009. 6 CDI rates may have leveled off, but they remain at historically high levels. These increases have been seen in pediatric and adult populations, but the elderly have been disproportionately affected. 6 CDI incidence has also increased in Canada and Europe. [7] [8] [9] Data on the changing epidemiology of CDI in pediatric patients are limited and are confounded by the prevalence of asymptomatic carriage of C. difficile among infants and very young children and by the presence of other pathogens among children with diarrhea and positive for C. difficile. [10] [11] [12] B. CDI with onset outside the hospital may be more common than previously recognized, with more than 50% of CDIs having onset in the community. In addition, more than 75% of CDI cases have onset outside the acute care hospital. 13 CDI present on admission to the hospital may increase the risk of CDI for other hospitalized patients. [14] [15] [16] C. There have been numerous reports of an increase in CDI severity. 8, 9, [17] [18] [19] Most reports of increases in the incidence and severity of CDI have been associated with the BI/ NAP1/027 strain of C. difficile. 8, 9, 18, 19 Some studies have found that this strain produces more toxin A and B in vitro than most other strains of C. difficile, and it may produce more spores. [20] [21] [22] It also produces a third toxin (binary toxin) and is highly resistant to fluoroquinolones. A strain commonly found in animals, polymerase chain reaction (PCR) ribotype 078 (which also has tcdC gene deletions and carries binary toxin), has been reported to have a higher 14-day mortality in the United Kingdom than BI/NAP1/027. 23 In the United Kingdom, the BI/ NAP1/027 strain is no longer the predominant strain, and it occurs less frequently in continental Europe. 7 In the United States, the prevalence of the BI/NAP1/027 strain averages approximately 25%-35% of CDI cases but ranges from 28% to 85% in adults. [24] [25] [26] II. Outcomes associated with CDI CDI is associated with increased length of hospital stay, costs, morbidity, and mortality in adult and pediatric patients. [27] [28] [29] [30] A. CDI increases hospital length of stay by 2.8 to 5.5 days. 28 B. Attributable costs of inpatient CDI in 2008 dollars have been estimated to be $3,006-$15,397 per episode. 28 US hospital costs for CDI management have been estimated to be $1.0-4.9 billion per year. 28 Costs of CDI in the outpatient and non-acute care settings have not been assessed. C. Patients with CDI were almost twice as likely to be discharged to a long-term care facility than propensity score-matched controls. 27 D. The attributable mortality of CDI is estimated to be 5%-10%, 8, 9, 23, 27 leading to an estimated 14,000-20,000 deaths attributable to CDI in the United States each year. 14, 29 III. Changing risk factors and possible decrease in CDI treatment response rates A. For the past 10 years, fluoroquinolones, previously infrequently associated with CDI, have been found to be one of the primary precipitating antimicrobials in recent studies. 19, 31 1. Virtually every antibiotic has been associated with CDI. Cephalosporins, ampicillin, and clindamycin remain important predisposing antibiotics. 15 B. Gastric acid suppression has been recognized as a risk factor for CDI in some studies. 15 1. Some studies suggest that the association between gastric acid suppression and CDI is related to other important risk factors, such as severity of illness and age. 31 2. Gastric acid suppression may be an important risk factor for CDI outside healthcare facilities.
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C. Several studies suggest that rates of response to treatment of CDI with metronidazole are declining, including a randomized, prospective, blinded, severity-stratified study that demonstrated statistically superior rates of response to vancomycin for severe disease but not for mild disease compared with metronidazole. 1. A CDI case is defined as a case of clinically significant diarrhea or toxic megacolon without other known etiology that meets one or more of the following criteria: (1) either the stool sample yields a positive result for a laboratory assay for C. difficile toxin A and/or B or a toxin-producing C. difficile organism is detected in the stool sample by culture or other means, (2) pseudomembranous colitis is seen on endoscopic examination or surgery, and (3) pseudomembranous colitis is seen on histopathological examination. a. The definition of clinically significant diarrhea has not been validated. Criteria used range from 3 or more than 3 diarrheal bowel movements within 24 hours or less to 6 diarrheal bowel movements in the previous 36 hours to at least 3 diarrheal bowel movements per day persisting for at least 2 days. Recent outbreaks of severe CDI indicate that it is not always possible to wait 24-48 hours before determining whether a patient has clinically significant diarrhea; therefore, diarrhea plus abdominal cramping has also been used to satisfy criteria for clinically significant diarrhea. 38,39 Conversely, it is normal for some patients to have 3 or more bowel movements per day. However, these are usually formed. Therefore, it is not possible to provide strict criteria for clinically significant diarrhea that can be applied to all patients. In general, clinically significant diarrhea in the context of CDI should consist of a sustained change in bowel movement consistency and/or frequency and/or abdominal 
Case type Definition
Healthcare facility-onset, healthcare facility-associated CDI CDI symptom onset more than 3 days after admission to a healthcare facility, with day of admission being day 1 Community-onset, healthcare facility-associated CDI CDI symptom onset in the community or less than or equal to 3 days from admission, provided symptom onset was less than 4 weeks after the last discharge from a healthcare facility Community-associated CDI CDI symptom onset in the community or less than or equal to 3 days after admission to a healthcare facility, provided that symptom onset was more than 12 weeks after the last discharge from a healthcare facility Indeterminate onset CDI CDI case patient who does not fit any of the above criteria for an exposure setting (eg, onset in the community greater than 4 weeks but less than 12 weeks after the last discharge from a healthcare facility) Unknown Exposure setting cannot be determined because of lack of available data Recurrent CDI An episode of CDI that occurs less than or equal to 8 weeks after the onset of a previous episode, provided that CDI symptoms from the earlier episode resolved note. When utilizing laboratory-based reporting symptoms, date and time of stool specimen collection can be used as a surrogate for symptom onset. If data on the time a patient was admitted (in addition to date) and/or the time stool was collected for testing are not available, CDI can be considered healthcare facility onset if stool is positive for toxigenic C. difficile or toxin after the third calendar day from hospital admission, where the first day is the day of admission (ie, a patient admitted on Monday with stool first positive for C. difficile toxin on Thursday or later is considered to have healthcare facility-onset CDI).
cramping in a patient without other identified causes. 2. Several CDI definitions have been proposed, including community-associated CDI; community-onset CDI, healthcare facility-associated CDI; healthcareonset CDI; and recurrent CDI. Healthcare facilities should track at least healthcare-onset CDI (Table 1) . 40 3. Surveillance for CDI is limited by variation in patient selection for testing, lower sensitivity of toxin enzyme immunoassays (EIAs), lower specificity of nucleic acid amplification tests (NAATs), and prolonged turnaround time for the cell cytotoxicity cell assay as well as stool culture for toxigenic C. difficile. 38,41,42 Lack of culture-based methods for routine diagnosis also limits the availability of strains for molecular typing, although at least one PCR test for C. difficile will provide a presumptive identification of the BI/NAP1/ 027 strain.
II. Identifying patients with CDI
Positive results of diarrheal stool tests for toxigenic C. difficile or its toxins are the most common methods to identify patients with CDI. The major difference among these 3 organisms is that C. difficile forms spores, whereas the other 2 do not. The formation of spores poses unique challenges for hand hygiene and environmental disinfection practices, since C. difficile spores are resistant to the bactericidal effects of alcohol and the most commonly used hospital disinfectants. Although alcohol-based hand hygiene products are ineffective at removing or disinfecting C. difficile spores in controlled laboratory experiments, no clinical study has demonstrated an increase in CDI with the use of these products or a decrease in CDI with soap and water. [62] [63] [64] [65] [66] [67] [68] Conversely, several of the studies did identify decreases in MRSA [63] [64] [65] 68 or VRE 64 associated with the use of alcohol-based hand hygiene products.
A recent intensive care unit-based study found admission to a room of a patient with CDI to be a risk factor for CDI, but 90% of patients who developed CDI did not have this risk factor. 69 Other studies that have examined sharing a room with a patient diagnosed with CDI or being admitted to a room after a patient with CDI was discharged from that room have not found these exposures to be risk factors for CDI.
59, [70] [71] [72] In addition, use of sporicidal methods to clean the environment outside of outbreak settings has not consistently demonstrated a reduction in CDI with these methods. [73] [74] [75] 1. IPC personnel must be able to identify CDI patients as soon as possible after they are diagnosed. This is necessary to ensure that patients are placed under contact precautions in a timely fashion. These data can also be used to calculate CDI rates. C. Ability to place patients with CDI under contact precautions. 1. Contact precautions require the ability to place patients in a private room (preferably) or to cohort patients with CDI as well as to place materials necessary for compliance with contact precautions (eg, gowns and gloves) in an easily accessible space outside the patient room. 2. Place a sign indicating that the patient is under contact precautions outside the patient's room. The sign should be in English and Spanish (or other language) if Spanish (or other language) is a commonly spoken language in the community or among healthcare providers. 3. If there are a limited number of single-bed rooms, patients with stool incontinence should preferentially be placed in private rooms. 4. If it is necessary to cohort patients, cohort patients colonized or infected with the same organism(s) (eg, do not cohort patients with CDI who are discordant on VRE or MRSA colonization status). 5. Dedicated equipment should be readily available for healthcare providers (eg, stethoscopes). If dedicated equipment is not available, responsibility for who will clean and disinfect equipment, when it will be cleaned and disinfected, and how it will be cleaned and disinfected must be clearly stated. I. High Highly confident that the true effect lies close to that of the estimated size and direction of the effect. Evidence is rated as high quality when there is a wide range of studies with no major limitations, there is little variation between studies, and the summary estimate has a narrow confidence interval. II. Moderate The true effect is likely to be close to the estimated size and direction of the effect, but there is a possibility that it is substantially different. Evidence is rated as moderate quality when there are only a few studies and some have limitations but not major flaws, there is some variation between studies, or the confidence interval of the summary estimate is wide.
III. Low
The true effect may be substantially different from the estimated size and direction of the effect. Evidence is rated as low quality when supporting studies have major flaws, there is important variation between studies, the confidence interval of the summary estimate is very wide, or there are no rigorous studies, only expert consensus.
note. Based on Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) 122 82 Some experts recommend continuing contact precautions for at least 48 hours after diarrhea resolves. (a) After resolution of symptoms, patients with CDI can continue to shed C. difficile in stool and contaminate the environment. 83 In addition, these patients are at high risk for recurrent CDI after treatment is stopped. At this time, data do not exist to support extending isolation as a measure to decrease CDI incidence. Therefore, extending contact precautions until discharge for all patients with CDI remains a special approach. 87, 88 Of note, one study did find a reduction in spores from the palmar surface of the hand with the alcohol-based hand hygiene product, 87 and another recent publication found that most hand-wash products produced a less than 1 log 10 reduction in spores despite a 60-second hand wash (30-second wash and 30-second rinse). 89 When considering whether to promote hand washing over alcoholbased hand hygiene products after caring for a patient with CDI, one should also consider that contamination of hands is less common when gloves are worn for the patient encounter; 59 in addition, as previously stated several clinical studies have not found an increase in CDI with alcohol-based hand hygiene products, but several did find reductions in MRSA or VRE. [62] [63] [64] [65] [66] [67] [68] II. Special approaches for preventing CDI When CDI incidence remains higher than the institution's goal, a CDI risk assessment should be performed.
Components of this risk assessment should include but not necessarily be limited to determining the location of new CDI cases within the affected area (ie, repeated cases in same room or cases scattered across multiple sites), the adequacy of contact precaution compliance, the adequacy of hand hygiene, and the adequacy of environment and equipment cleaning. Meetings with leadership and healthcare workers in the affected area should be conducted to identify potential opportunities to improve the CDI prevention plan. Contact the laboratory that performs the C. difficile assay(s) to determine whether there have been any changes in assay or assay performance. 45 In addition to ensuring compliance with the basic recommendations, special approaches may be added to the CDI prevention program. However, there are several unresolved issues regarding CDI prevention. This is apparent when reviewing the rankings of each recommendation on the basis of the quality of the data to support it. As a result, implementation of the recommendations beyond the basic practices to prevent CDI should be individualized at each healthcare facility. One may consider a tiered approach in which recommendations are instituted individually or in groups; additional tiers are added if CDI rates do not improve, with implementation of basic practices as the first tier. Subsequent tiers should be prioritized on the basis of the CDI risk assessment. A. Approaches to minimize C. difficile transmission by HCP However, patients with recent CDI are a subset of asymptomatic carriers for whom prolongation of contact precautions may be considered as a special approach if basic measures are unsuccessful. The rationale is that these patients are at high risk for recurrence and continued shedding is common for several weeks after successful treatment. How to manage patients found to be colonized with C. difficile but without prior or present CDI is unclear (eg, a patient positive by PCR but without clinically significant diarrhea). The benefits of placing these patients under contact precautions (decreased transmission of C. difficile to other patients) must be balanced with the risks (in the absence of universal screening, it will be unlikely to impact CDI incidence) and potential for adverse events due to contact precautions. [103] [104] [105] [106] e. Do not attempt to decolonize asymptomatic patients since this has not been effective and may increase the patient's risk of developing CDI in the future. 102 2. C. difficile testing should not be repeated at the end of successful therapy in a patient recently treated for CDI (quality of evidence: III). a. A positive test may result in unnecessary prolongation of contact precautions and CDI treatment. i. In some settings, contact precautions may be extended until hospital discharge after symptom resolution. However, there are insufficient data to recommend extending the duration of contact precautions on the basis of whether C. difficile or its toxins can be detected in the patient's stool. b. A positive test at the end of therapy does not predict who will develop a recurrence or relapse. 107 c. Repeat C. difficile testing does not provide any useful clinical information but does require nursing time to collect the specimen and laboratory technician time to perform the test and report results. d. It is not appropriate for healthcare facilities to request repeat C. difficile testing in a patient prior to transfer in the absence of a clinical syndrome consistent with an undiagnosed and/or untreated case of CDI. 3. Do not routinely place patients who are on antimicrobials for other indications on CDI treatment to prevent CDI (quality of evidence: III). a. Unnecessary treatment for CDI may increase the patient's risk of developing CDI in the future.
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IV. Unresolved issues 1. Use of gowns and gloves by family members and other visitors. a. The utility of requiring family members and other visitors to wear gowns and gloves to prevent C. difficile transmission is unknown. 108 The risk that family members and other visitors will transmit C. difficile between patients is likely to be related to the degree of contact the visitor has with the patient and the patient's environment, whether the visitor performs hand hygiene, and the degree of interaction the visitor has with other patients. At a minimum, family members and other visitors should be instructed to perform hand hygiene whenever entering or leaving the patient's room. If family members do not wear gowns and gloves, they should be educated and instructed to use proper hand washing technique prior to leaving the patient's room. 2. Standing orders or nurse-driven protocols to test patients with diarrhea for C. difficile. a. Nurses frequently identify patients with diarrhea before the treating physician does. b. If nurses are permitted to send a stool specimen for C. difficile testing prior to obtaining a physician order, they should be educated on proper patient selection for C. difficile testing (ie, clinically significant diarrhea in a patient without other reasons for clinically significant diarrhea). 3. Admission-based alert systems that notify IPC and clinical personnel about readmitted or transferred patients with a history of CDI. a. This information can be integrated into a computerized database used during admission and registration or a separate electronic or paper-based database. i. If an alert system is implemented, patients with a history of CDI should be placed under contact precautions if they are readmitted only if they have symptoms consistent with CDI on admission. Asymptomatic patients with a history of CDI do not require contact precautions. ii. The duration that the alert should remain active is unknown. Nearly all cases of recurrent CDI occur within 90 days of the last episode. In light of this, it is reasonable to eliminate the alert after 90 days from the last episode of CDI. However, healthcare facilities may not be aware of recurrent episodes of CDI that are diagnosed and managed in outpatient settings, so an arbitrary cutoff based on the last known episode of CDI may inadvertently remove patients with ongoing recurrent CDI. 4. Ongoing assessment of CDI knowledge and intensified CDI education among HCP. a. Reeducate staff if prior CDI training occurred more than 12 months earlier or if overall knowledge is deemed to be inadequate. i. Include environmental service personnel in educational efforts. 5. Restricting the use of gastric acid suppressants.
a. Whether gastric acid suppressants are a contributing cause of CDI or a marker for patients at risk for CDI is not clear. There are no data suggesting restricting gastric acid suppressants is associated with reductions in CDI. 6. Prescribing probiotics as primary prophylaxis.
a. Recent meta-analyses indicated that probiotics may be effective as primary prophylaxis against CDI. 109, 110 A concern with these meta-analyses is that the studies with the greatest weight had extremely high incidences of CDI in the placebo groups (7%, 24%, and 40%). The incidence of CDI in high-risk patients without contraindications to probiotics is typically less than or equal to 3%. 111, 112 The high incidence of CDI in the placebo group has the potential to bias their findings to favor the probiotics. For example, a recent large randomized controlled trial of probiotic versus placebo with a more typical CDI incidence in the placebo arm (1.2%) failed to demonstrate a reduction in CDI with the use of a probiotic. 113 In addition, many hospitalized patients have relative contraindications to probiotics (eg, central venous catheter, immunocompromised) that place them at increased risk of infection due to the probiotic strain(s). 114 7. No-touch disinfection technologies.
a. Several no-touch disinfection products are commercially available. In general, these products use ultraviolet light or hydrogen peroxide vapor to disinfect the environment. 73, 92, 115 These devices kill C. difficile spores, and several studies have found them to be effective at reducing cultivatable C. difficile from patient rooms. 73, 92, 115 Although sporicidal activity can be achieved without requiring a person to wipe down a surface, the use of these devices does not preclude the need to manually clean soiled surfaces. 73, 92 Data are currently too limited to draw any conclusions as to whether or when these devices should be a component of a CDI prevention program. In addition, excellent results can be achieved with manual cleaning with a sporicidal disinfectant. Senior management is responsible for ensuring that the healthcare system supports an infection prevention and control (IPC) program that effectively prevents healthcare-associated infections (HAIs) and the transmission of epidemiologically important pathogens Senior management is accountable for ensuring that an adequate number of trained personnel are assigned to the IPC program and adequate staffing of other departments that play a key role in HAI prevention (eg, environmental services) Senior management is accountable for ensuring that healthcare personnel, including licensed and nonlicensed personnel, are adequately trained and competent to perform their job responsibilities Direct healthcare providers (such as physicians, nurses, aides, and therapists) and ancillary personnel (such as environmental service and equipment processing personnel) are responsible for ensuring that appropriate IPC practices are used at all times (including hand hygiene, standard and isolation precautions, and cleaning and disinfection of equipment and the environment) Senior and unit leaders are responsible for holding personnel accountable for their actions IPC leadership is responsible for ensuring that an active program to identify HAIs is implemented, that HAI data are analyzed and regularly provided to those who can use the information to improve the quality of care (eg, unit staff, clinicians, and hospital administrators), and that evidence-based practices are incorporated into the program Senior and unit leaders are accountable for ensuring that appropriate training and educational programs to prevent HAIs are developed and provided to personnel, patients, and families Personnel from the IPC program, the laboratory, and information technology departments are responsible for ensuring that systems are in place to support the surveillance program nition used; see Table 1 ). ii. Denominator: total number of patient-days in the population being monitored. iii. Multiply by 10,000 so that the measure is expressed as the number of cases per 10,000 patient-days (note: to convert the rate per 10,000 patient-days to 1,000 patient-days, divide the rate by 10; conversely, to convert a rate from 1,000 patient-days to 10,000 patient-days, multiply the rate by 10).
II. External reporting
There are many challenges in providing useful information to consumers and other stakeholders while preventing unintended adverse consequences of public reporting of HAIs. 116 Recommendations for public reporting of HAIs have been provided by the Hospital Infection Control Practices Advisory Committee, the Healthcare-Associated Infection Working Group of the Joint Public Policy Committee, and the National Quality Forum. 116, 117 A. State and federal requirements 1. The CMS began requiring acute care hospitals participating in their Inpatient Prospective Payment System to report laboratory-identified CDI using NHSN in January 2013. 2. For information on local requirements, check with your state or local health department. B. External quality initiatives 1. Hospitals that participate in external quality initiatives must collect and report the data if required by the initiative.
section 6: examples of implementation strategies
Accountability is an essential principle for preventing HAIs. It provides the necessary translational link between science and implementation. Without clear accountability, scientifically based implementation strategies will be used in an inconsistent and fragmented way, decreasing their effectiveness in preventing HAIs. Accountability begins with the chief executive officer and other senior leaders who provide the imperative for HAI prevention, thereby making HAI prevention an organizational priority. Senior leadership is accountable for providing adequate resources needed for effective implementation of an HAI prevention program. These resources include necessary personnel (clinical and nonclinical), education, and equipment (Table 3) . Successful implementation strategies used as part of collaboratives and working groups include engage, educate, execute, and evaluate. 96, 118 Strategies that have been shown to be effective in addressing CDI within healthcare settings are provided in this section. 
